COX-1 and vascular disease

Clinical Pharmacology and Therapeutics

Volumn 86, Issue 2, 2009, Pages 212-215

  Vanhoutte, P M ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ACETYLSALICYLIC ACID; CALCIMYCIN; CALCIUM; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ENDOTHELIUM DERIVED CONSTRICTING FACTOR; ENDOTHELIUM DERIVED RELAXING FACTOR; INDOMETACIN; NITRIC OXIDE; PROSTACYCLIN; PROSTACYCLIN SYNTHASE; PROSTANOID; PROSTANOID RECEPTOR; TERUTROBAN; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; THROMBOXANE RECEPTOR; THROMBOXANE RECEPTOR BLOCKING AGENT;

AGING; ATHEROGENESIS; ATHEROSCLEROSIS; BIOASSAY; CALCIUM TRANSPORT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME INHIBITION; ENZYME RELEASE; GENE OVEREXPRESSION; HUMAN; HYPERTENSION; IN VITRO STUDY; MOLECULAR MECHANICS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SHORT SURVEY; SMOOTH MUSCLE RELAXATION; TREATMENT RESPONSE; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VASODILATATION;

AGING; ANIMALS; BLOOD PLATELETS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DIABETES MELLITUS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; NITRIC OXIDE SYNTHASE; PLATELET AGGREGATION INHIBITORS; PROSTAGLANDINS; THROMBOSIS; THROMBOXANE A2; VASOCONSTRICTION; VASODILATION;

EID: 67651166598     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.108     Document Type: Short Survey

References (30)

1. Furchgott, R.F. & Zawadzki, J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288, 373-376 (1980).
2. Furchgott, R.F. Studies on relaxation of rabbit aorta by sodium nitrite: the basis for the proposal that acid-activatable inhibitory factor from bovine retractor penis is inorganic nitrite and the endothelium-derived relaxing factor is nitric oxide. In Vasodilatation: Vascular Smooth Muscle, Peptides, Autonomic Nerves and Endothelium (ed. Vanhoutte, P.M.) 401-414 (Raven Press, New York, 1988).
3. Ignarro, L.J., Byrns, R.E. & Wood, K.S. Biochemical and pharmacological properties of endothelium-derived relaxing factor and its similarity to nitric oxide radical. In Vasodilatation: Vascular Smooth Muscle, Peptides, Autonomic Nerves and Endothelium (ed. Vanhoutte, P.M. ed.) 427-436 (Raven Press, NewYork, 1988).
4. Moncada, S. Nitric oxide in the vasculature: physiology and pathophysiology. Ann. N. Y. Acad. Sci. 811, 60-7; discussion 67 (1997).
5. Busse, R., Edwards, G., Félétou, M., Fleming, I., Vanhoutte, P.M. & Weston, A.H. EDHF: bringing the concepts together. Trends Pharmacol. Sci. 23, 374-380 (2002).
6. Félétou, M. & Vanhoutte, P.M. EDHF: The Complete Story 1-298 (CRC Taylor & Francis, Boca Raton, 2006).
7. De Mey, J.G. & Vanhoutte, P.M. Heterogeneous behavior of the canine arterial and venous wall. Importance of the endothelium. Circ. Res. 51, 439-447 (1982).
8. Furchgott, R.F. & Vanhoutte, P.M. Endothelium-derived relaxing and contracting factors. FASEB J. 3, 2007-2018 (1989).
9. Vanhoutte, P.M., Feletou, M. & Taddei, S. Endothelium-dependent contractions in hypertension. Br. J. Pharmacol. 144, 449-458 (2005).
10. Félétou, M. & Vanhoutte, P.M. Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am. J. Physiol. Heart Circ. Physiol. 291, H985-H1002 (2006).
11. Vanhoutte, P.M., Shimokawa, H., Tang, E. & Félétou, M. Endothelial dysfunction and vascular disease. Acta Physiol. 196, 193-222 (2009).
12. Félétou, M., Tang, E.H.C. & Vanhoutte, P.M. Nitric oxide the gatekeeper of endothelial vasomotor control. Front Biosci. 13, 4198-4217 (2008).
13. Vanhoutte, P.M. & Tang, E.H. Endothelium-dependent contractions: when a good guy turns bad! J. Physiol. (Lond.) 586, 5295-5304 (2008).
14. Wong, S.L. et al. Cyclooxygenase-2-derived prostaglandin F2alpha mediates endothelium-dependent contractions in the aortae of hamsters with increased impact during aging. Circ. Res. 104, 228-235 (2009).
15. Tesfamariam, B. Free radicals in diabetic endothelial cell dysfunction. Free Radic. Biol. Med. 16, 383-391 (1994).
16. De Vriese, A.S., Verbeuren, T.J., Van de Voorde, J., Lameire, N.H. & Vanhoutte, P.M. Endothelial dysfunction in diabetes. Br. J. Pharmacol. 130, 963-974 (2000).
17. Taddei, S. et al. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 91, 1981-1987 (1995).
18. Taddei, S., Virdis, A., Ghiadoni, L., Magagna, A. & Salvetti, A. Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension. Hypertension 29, 274-279 (1997).
19. Taddei, S. et al. Hypertension causes premature aging of endothelial function in humans. Hypertension 29, 736-743 (1997).
20. Monobe, H., Yamanari, H., Nakamura, K. & Ohe, T. Effects of low-dose aspirin on endothelial function in hypertensive patients. Clin. Cardiol. 24, 705-709 (2001).
21. Lüscher, T.F., Cooke, J.P., Houston, D.S., Neves, R.J. & Vanhoutte, P.M. Endothelium-dependent relaxation in human arteries. Mayo Clin Proc 62, 601-606 (1997).
22. Husain, S., Andrews, N.P., Mulcahy, D., Panza, J.A. & Quyyumi, A.A. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation 97, 716-720 (1998).
23. Belhassen, L., Pelle, G., Dubois-Rande, J.L. & Adnot, S. Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. J. Am. Coll. Cardiol. 41, 1198-1204 (2003).
24. Arehart, E. et al. Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. Circ. Res. 102, 986-993 (2008).
25. Flavahan, N.A. Balancing prostanoid activity in the human vascular system. Trends Pharmacol. Sci. 28, 106-110 (2007).
26. Therland, K.L. et al. Cycloxygenase-2 is expressed in vasculature of normal and ischemic adult human kidney and is colocalized with vascular prostaglandin E2 EP4 receptors. J. Am. Soc. Nephrol. 15, 1189-1198 (2004).
27. Verma, S., Raj, S.R., Shewchuk, L., Mather, K.J. & Anderson, T.J. Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation. Circulation 104, 2879-2882 (2001).
28. Title, L.M., Giddens, K., McInerney, M.M., McQueen, M.J. & Nassar, B.A. Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. J. Am. Coll. Cardiol. 42, 1747-1753 (2003).
29. Bogaty, P. et al. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study. Circulation 110, 934-939 (2004).
30. Lekakis, J.P. et al. Divergent effects of rofecoxib on endothelial function and inflammation in acute coronary syndromes. Int. J. Cardiol. 112, 359-366 (2006).